Clinical characteristics | | | |
Age (years) | 92 | 12.7 (3.4) | NA |
Male gender, n (%) | 92 | 64 (70) | NA |
Body mass index (kg/m2) | 92 | 19.0 (3.5) | NA |
Disease severity score (range 6–30) | 92 | 11 (9–14) | NA |
Atopic features | | | |
Plasma total IgE concentration (kU/l) | 92 | 611 (271–1256) | ⩽160 for 7 years; ⩽180 for ⩾8 years |
Specific IgE to D pteronyssinus (kU/l) | 92 | 105 (39–145) | <0.35 |
Peripheral blood eosinophil (%) | 92 | 8 (5–10) | ⩽3 |
Absolute eosinophil count (109/l) | 92 | 0.52 (0.35–0.77) | ⩽0.25 |
Lung function† | | | |
FEV1 predicted (%) | 80 | 92.1 (15.9) | ⩾80 |
FVC predicted (%) | 80 | 104.8 (17.3) | ⩾80 |
FEV1/FVC (%) | 80 | 80.0 (9.6) | ⩾80 |
PD20 (μmol) | 68 | 1.95 (0.58–6.00) | >7.8 |
Inflammatory markers‡ | | | |
Feno (ppb) | 92 | 72.4 (39.5–117.8) | ⩽30 |
Plasma TARC concentration (pg/ml) | 92 | 45.0 (26.8–85.3) | ⩽70 |
Plasma MDC concentration (pg/ml) | 92 | 540 (411–702) | ⩽480 |
Plasma eotaxin concentration (pg/ml) | 92 | 39.0 (33.5–47.5) | ⩽45 |
EBC MDC concentration (pg/ml) | 92 | 113 (93–126) | ⩽105 |
EBC eotaxin concentration (pg/ml) | 92 | 37.0 (33.0–43.3) | ⩽35 |
EBC LTB4 concentration (pg/ml) | 92 | 39.9 (31.4–47.7) | ⩽35 |